Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. Both paliperidone and risperidone are second generation antipsychotics，but have same pharmacological effects of antipsychotic treatment and paliperidone may have more efficacy and safty.This study was designed to examine the acute efficacy, safety, and tolerability of paliperidone and risperidone for patients with MAP.
Methods:A Multiple-Center, Randomized, Double-Blind.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
The Second Xiangya Hospital of Central University
Changsha, Hunan, China
The severity of psychosis
Positive and Negative Syndrome Scale
Time frame: up to 4 weeks. participants will be followed for the duration of hospital stay
Clinical general status
Clinical general rating scale
Time frame: up to 4 weeks. participants will be followed for the duration of hospital stay
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.